

Mark B Pepys

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8432822/publications.pdf>

Version: 2024-02-01

136
papers

30,890
citations

15466

65
h-index

11581

135
g-index

137
all docs

137
docs citations

137
times ranked

28072
citing authors

#	ARTICLE	IF	CITATIONS
1	Transthyretin amyloidosis: new answers but many questions. <i>Journal of Internal Medicine</i> , 2021, 289, 933-935.	2.7	0
2	C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?. <i>European Heart Journal</i> , 2021, 42, 2280-2283.	1.0	24
3	Dementia in the older population is associated with neocortex content of serum amyloid P component. <i>Brain Communications</i> , 2021, 3, fcab225.	1.5	5
4	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. <i>Nature Communications</i> , 2021, 12, 7112.	5.8	13
5	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. <i>Journal of Biological Chemistry</i> , 2020, 295, 11379-11387.	1.6	12
6	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8274-8283.	2.9	25
7	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	94
8	The Pentraxins 1975â€“2018: Serendipity, Diagnostics and Drugs. <i>Frontiers in Immunology</i> , 2018, 9, 2382.	2.2	49
9	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. <i>PLoS ONE</i> , 2018, 13, e0197299.	1.1	13
10	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. <i>Journal of Biological Chemistry</i> , 2018, 293, 14192-14199.	1.6	68
11	Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 5-6.	1.4	2
12	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. <i>Journal of Proteomics</i> , 2017, 165, 113-118.	1.2	14
13	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular A β amyloid deposits<i>in vivo</i>. <i>Open Biology</i> , 2016, 6, 150202.	1.5	21
14	A novel mechanoâ€“enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. <i>EMBO Molecular Medicine</i> , 2015, 7, 1337-1349.	3.3	109
15	Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction. <i>Cell Reports</i> , 2015, 13, 1937-1948.	2.9	123
16	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 2015, 373, 1106-1114.	13.9	304
17	Bifunctional crosslinking ligands for transthyretin. <i>Open Biology</i> , 2015, 5, 150105.	1.5	2
18	Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP). <i>Blood</i> , 2015, 126, 1836-1836.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers. <i>Circulation Research</i> , 2014, 114, 672-676.	2.0	63
20	Attention to Detail in the Selection of Words in Epidemiologic Research Reports. <i>American Journal of Epidemiology</i> , 2014, 179, 795-796.	1.6	2
21	Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component. <i>Infection and Immunity</i> , 2014, 82, 1872-1879.	1.0	22
22	Interaction of serum amyloid P component with hexanoyl bis(DL-proline) (CPHPC). <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2014, 70, 2232-2240.	2.5	11
23	C-reactive protein is essential for innate resistance to pneumococcal infection. <i>Immunology</i> , 2014, 142, 414-420.	2.0	51
24	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1539-1544.	3.3	91
25	Targeted treatment for amyloidosis. <i>Israel Medical Association Journal</i> , 2014, 16, 277-80.	0.1	5
26	Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. <i>Journal of Immunological Methods</i> , 2013, 390, 63-73.	0.6	33
27	Pathogenetic mechanisms of amyloid A amyloidosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16115-16120.	3.3	79
28	Structure, Folding Dynamics, and Amyloidogenesis of D76N β 2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2013, 288, 30917-30930.	1.6	80
29	Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 93-98.	1.4	7
30	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. <i>New England Journal of Medicine</i> , 2012, 367, 1310-1320.	13.9	909
31	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β 2-Microglobulin. <i>New England Journal of Medicine</i> , 2012, 366, 2276-2283.	13.9	172
32	Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. <i>Journal of Immunological Methods</i> , 2012, 384, 92-102.	0.6	32
33	Immunoradiometric assay for human serum amyloid P component. <i>Journal of Immunological Methods</i> , 2011, 371, 18-24.	0.6	6
34	Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. <i>Journal of Molecular Recognition</i> , 2011, 24, 371-377.	1.1	34
35	Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. <i>BMJ: British Medical Journal</i> , 2011, 342, d548-d548.	2.4	530
36	Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 245-249.	6.7	17

#	ARTICLE	IF	CITATIONS
37	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. <i>British Journal of Haematology</i> , 2010, 148, 760-767.	1.2	106
38	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. <i>Nature</i> , 2010, 468, 93-97.	13.7	290
39	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20483-20488.	3.3	55
40	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. <i>Lancet</i> , The, 2010, 375, 132-140.	6.3	1,946
41	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7619-7623.	3.3	63
42	C-Reactive Protein and Coronary Disease. <i>Circulation</i> , 2009, 120, 2036-2039.	1.6	49
43	A molecular correlate of clinicopathology in transthyretin amyloidosis. <i>Journal of Pathology</i> , 2009, 217, 1-3.	2.1	16
44	Jack Pepys (May 15, 1914â€“September 9, 1996): A personal recollection. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 718-720.	1.5	1
45	C-reactive protein is neither a marker nor a mediator of atherosclerosis. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 234-235.	2.0	29
46	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE ^{0/0} mice. <i>Atherosclerosis</i> , 2008, 196, 248-255.	0.4	96
47	Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. <i>Journal of Biological Chemistry</i> , 2008, 283, 30451-30460.	1.6	82
48	Science and serendipity. <i>Clinical Medicine</i> , 2007, 7, 562-578.	0.8	27
49	Human plasma fibrinogen is synthesized in the liver. <i>Blood</i> , 2007, 109, 1971-1974.	0.6	251
50	Î²-Edge Interactions in a Pentadecameric Human Antibody V _H Domain. <i>Journal of Molecular Biology</i> , 2007, 367, 603-608.	2.0	13
51	Normal circulating serum amyloid P component concentration in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2013-2017.	6.7	14
52	Is leptin an important physiological regulator of CRP?. <i>Nature Medicine</i> , 2007, 13, 17-18.	15.2	14
53	C-reactive protein and cardiovascular disease: Weighing the evidence. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 72-79.	0.8	1
54	Amyloidosis. <i>Annual Review of Medicine</i> , 2006, 57, 223-241.	5.0	557

#	ARTICLE	IF	CITATIONS
55	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. <i>Blood</i> , 2006, 107, 1227-1229.	0.6	113
56	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , 2006, 440, 1217-1221.	13.7	621
57	C-reactive protein and cardiovascular disease: Weighing the evidence. <i>Current Atherosclerosis Reports</i> , 2006, 8, 421-428.	2.0	75
58	Human Serum Amyloid P Component Protects against Escherichia coli O157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolytic-Uremic Syndrome. <i>Journal of Infectious Diseases</i> , 2006, 193, 1120-1124.	1.9	48
59	CRP or not CRP? That Is the Question. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1091-1094.	1.1	98
60	Inflammation and Endothelial Function. <i>Circulation</i> , 2005, 111, 1530-1536.	1.6	175
61	Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself. <i>Circulation Research</i> , 2005, 97, e97-103.	2.0	121
62	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8309-8314.	3.3	194
63	Genetic Effects on Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A Comparison of Monozygotic and Dizygotic Twins. <i>Clinical Chemistry</i> , 2004, 50, 130-134.	1.5	139
64	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. <i>Immunology</i> , 2004, 112, 255-264.	2.0	63
65	Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice. <i>Immunology</i> , 2004, 112, 250-254.	2.0	2
66	Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 1214-1218.	2.4	137
67	Obesity Is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences. <i>Circulation</i> , 2004, 109, 3022-3028.	1.6	168
68	C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2004, 350, 1387-1397.	13.9	2,608
69	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. <i>British Journal of Haematology</i> , 2003, 122, 78-84.	1.2	370
70	MHC typing in variant Creutzfeldt-Jakob disease. <i>Lancet</i> , 2003, 361, 487-489.	6.3	24
71	Markers of inflammation in women on different hormone replacement therapies. <i>Annals of Medicine</i> , 2003, 35, 353-361.	1.5	27
72	Refinement of the Association of Serum C-reactive Protein Concentration and Coronary Heart Disease Risk by Correction for Within-Subject Variation over Time: The MONICA Augsburg Studies, 1984 and 1987. <i>American Journal of Epidemiology</i> , 2003, 158, 357-364.	1.6	111

#	ARTICLE	IF	CITATIONS
73	Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays. <i>Clinical Chemistry</i> , 2003, 49, 1691-1695.	1.5	30
74	Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice. <i>Journal of Immunology</i> , 2003, 171, 6046-6051.	0.4	33
75	Dame Sheila Patricia Violet Sherlock. 31 March 1918 – 30 December 2001 Elected FRS 2001. <i>Biographical Memoirs of Fellows of the Royal Society</i> , 2003, 49, 475-493.	0.1	2
76	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	1,673
77	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	2,941
78	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. <i>New England Journal of Medicine</i> , 2002, 346, 1786-1791.	13.9	621
79	Production of Granulocyte Colony-Stimulating Factor in the Nonspecific Acute Phase Response Enhances Host Resistance to Bacterial Infection. <i>Journal of Immunology</i> , 2002, 169, 913-919.	0.4	47
80	C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity. <i>Annals of Internal Medicine</i> , 2002, 136, 550.	2.0	21
81	Influenza virus infection is not affected by serum amyloid P component. <i>Molecular Medicine</i> , 2002, 8, 9-15.	1.9	9
82	Lack of seasonal variation in C-reactive protein. <i>Clinical Chemistry</i> , 2002, 48, 575-7.	1.5	10
83	Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. <i>Journal of Molecular Biology</i> , 2001, 311, 241-247.	2.0	110
84	Effect of alcohol consumption on systemic markers of inflammation. <i>Lancet</i> , The, 2001, 357, 763-767.	6.3	496
85	Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. <i>Lancet</i> , The, 2001, 358, 24-29.	6.3	520
86	Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. <i>Nature Medicine</i> , 2001, 7, 485-487.	15.2	206
87	C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites. <i>Circulation</i> , 2001, 104, 145-150.	1.6	382
88	LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS.. <i>Transplantation</i> , 2000, 69, S139.	0.5	0
89	Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. <i>Clinical Chemistry</i> , 2000, 46, 934-938.	1.5	218
90	The protofilament substructure of amyloid fibrils ¹¹ Edited by F. E. Cohen. <i>Journal of Molecular Biology</i> , 2000, 300, 1033-1039.	2.0	332

#	ARTICLE	IF	CITATIONS
91	Molecular chaperone properties of serum amyloid P component. FEBS Letters, 2000, 473, 199-202.	1.3	49
92	Infection With <i>Helicobacter pylori</i> Is Not a Major Independent Risk Factor for Stable Coronary Heart Disease. Circulation, 1999, 100, 2326-2331.	1.6	83
93	The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 1999, 7, 169-177.	1.6	656
94	Acute phase response and evolution of familial Mediter ranean fever. Lancet, The, 1999, 353, 1415.	6.3	160
95	C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men. Circulation, 1999, 99, 237-242.	1.6	1,672
96	Enhanced inflammatory response in patients with preinfarction unstable angina. Journal of the American College of Cardiology, 1999, 34, 1696-1703.	1.2	144
97	Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrology Dialysis Transplantation, 1999, 14, 2639-2644.	0.4	72
98	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 709-713.	3.3	68
99	Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney International, 1998, 53, 276-281.	2.6	70
100	SAA ¹ alleles as risk factors in reactive systemic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 262-265.	1.4	104
101	Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina. Circulation, 1998, 98, 2370-2376.	1.6	292
102	Interleukin 6 Influences Germinal Center Development and Antibody Production via a Contribution of C3 Complement Component. Journal of Experimental Medicine, 1998, 188, 1895-1906.	4.2	177
103	Scintigraphy with ¹²³ I-Serum Amyloid P Component in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 208-210.	0.6	21
104	Rapid Automated High Sensitivity Enzyme Immunoassay of C-Reactive Protein. Clinical Chemistry, 1998, 44, 1358-1361.	1.5	123
105	DOMINO HEPATIC TRANSPLANTATION USING THE LIVER FROM A PATIENT WITH FAMILIAL AMYLOID POLYNEUROPATHY. Transplantation, 1998, 65, 1496-1498.	0.5	55
106	Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age and Ageing, 1997, 26, 153-158.	0.7	57
107	Amyloid and the Gut. Digestive Diseases, 1997, 15, 155-171.	0.8	36
108	Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. Journal of Molecular Biology, 1997, 269, 570-578.	2.0	43

#	ARTICLE	IF	CITATIONS
109	Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses 1 Edited by R. Huber. <i>Journal of Molecular Biology</i> , 1997, 272, 408-422.	2.0	113
110	Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 Edited by F. E. Cohen. <i>Journal of Molecular Biology</i> , 1997, 273, 729-739.	2.0	1,590
111	The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: Homology to self and the selection of T cell epitopes and T cell receptors. <i>Molecular Immunology</i> , 1997, 34, 115-124.	1.0	8
112	Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. <i>Nature Medicine</i> , 1997, 3, 855-859.	15.2	239
113	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. <i>Nature</i> , 1997, 385, 787-793.	13.7	1,061
114	Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. <i>American Journal of Cardiology</i> , 1997, 80, 1104-1108.	0.7	10
115	AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS. <i>British Journal of Haematology</i> , 1997, 99, 245-256.	1.2	166
116	Three dimensional structure of human C-reactive protein. <i>Nature Structural and Molecular Biology</i> , 1996, 3, 346-354.	3.6	308
117	Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. <i>Kidney International</i> , 1996, 50, 282-289.	2.6	56
118	Plasma Protein Acute-Phase Response in Unstable Angina Is Not Induced by Ischemic Injury. <i>Circulation</i> , 1996, 94, 2373-2380.	1.6	134
119	Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice. <i>European Journal of Immunology</i> , 1995, 25, 3489-3495.	1.6	18
120	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995, 2, 163-166.	1.4	7
121	The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina. <i>New England Journal of Medicine</i> , 1994, 331, 417-424.	13.9	2,159
122	Structure of pentameric human serum amyloid P component. <i>Nature</i> , 1994, 367, 338-345.	13.7	471
123	Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. <i>Structure</i> , 1994, 2, 1017-1027.	1.6	96
124	Molecular characterization of <i>Limulus polyphemus</i> C-reactive protein. I. Subunit composition. <i>FEBS Journal</i> , 1993, 214, 91-97.	0.2	42
125	Molecular characterization of <i>Limulus Polyphemus</i> C-reactive protein. II. Asparagine-linked oligosaccharides. <i>FEBS Journal</i> , 1993, 214, 99-110.	0.2	13
126	Serum amyloid P component in chronic renal failure and dialysis. <i>Clinica Chimica Acta</i> , 1991, 200, 191-199.	0.5	79

#	ARTICLE	IF	CITATIONS
127	Tissue Vitronectin in Normal Adult Human Dermis Is Non-Covalently Bound to Elastic Tissue. Journal of Investigative Dermatology, 1991, 96, 747-753.	0.3	22
128	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP α met ³⁰). Clinical Genetics, 1991, 40, 242-246.	1.0	350
129	Evaluation of Systemic Amyloidosis by Scintigraphy with ¹²³ I-Labeled Serum Amyloid P Component. New England Journal of Medicine, 1990, 323, 508-513.	13.9	497
130	Tissue Amyloid P Component in Normal Human Dermis is Non-covalently Associated with Elastic Fiber Microfibrils. Journal of Investigative Dermatology, 1989, 92, 53-58.	0.3	21
131	Amyloid P Component Binds to Keratin Bodies in Human Skin and to Isolated Keratin Filament Aggregates In Vitro. Journal of Investigative Dermatology, 1988, 91, 22-28.	0.3	35
132	Imaging of experimental amyloidosis with ¹³¹ I-labeled serum amyloid p component. Arthritis and Rheumatism, 1987, 30, 1303-1306.	6.7	26
133	Murine type II collagen arthritis: Association of an acute-phase response with clinical course. Arthritis and Rheumatism, 1986, 29, 1131-1138.	6.7	12
134	Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. European Journal of Clinical Investigation, 1985, 15, 89-94.	1.7	15
135	Serum C-reactive protein levels in the management of infection in acute leukaemia. European Journal of Cancer & Clinical Oncology, 1984, 20, 319-325.	0.9	35
136	Immunohistochemical Studies of Amyloid P Component Distribution in Normal Human Skin. Journal of Investigative Dermatology, 1983, 80, 86-90.	0.3	43